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Abstract
S1P (sphingosine 1-phosphate) is a bioactive lipid which, after release from cells via certain transporters, acts as
a ligand for a family of five S1P-specific G protein-coupled receptors (S1P1-5). However, it also has a number of
intracellular targets. S1P is formed by the ATP-dependent phosphorylation of sphingosine, catalysed by two
isoforms of sphingosine kinase (EC 2.7.1.91). It can be dephosphorylated back to sphingosine by sphingosine
1-phosphate phosphatase (EC 3.1.3) or cleaved into phosphoethanolamine and hexadecenal by sphingosine 1-
phosphate lyase (EC 4.1.2.27). Recessive mutations in the S1P lyase (SPL) gene underlie a recently identified
sphingolipidosis: SPL Insufficiency Syndrome (SPLIS). In general, S1P promotes cell survival, proliferation,
migration, adhesion and inhibition of apoptosis. Intracellular S1P affects epigenetic regulation, endosomal
processing, mitochondrial function and cell proliferation/senescence. S1P has myriad physiological functions,
including vascular development, lymphocyte trafficking and neurogenesis. However, S1P is also involved in a
number of diseases such as cancer, inflammation and fibrosis. Therefore, its GPCRs and enzymes of synthesis
and degradation are a major focus for drug discovery.
Contents
This is a citation summary for Sphingosine 1-phosphate turnover in the Guide to Pharmacology database
(GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the
database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database
which are given here under database links.
GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a
reference work which is most usefully represented as an on-line database. As in any publication this work
should be appropriately cited, and the papers it cites should also be recognized. This document provides a
citation for the relevant parts of the database, and also provides a reference list for the research cited by those
parts.
Please note that the database version for the citations given in GtoPdb are to the most recent preceding version
in which the family or its subfamilies and targets were substantially changed. The links below are to the current






    Sphingosine kinase
    http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=787
        Enzymes
                SPHK1(sphingosine kinase 1)
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2204
                SPHK2(sphingosine kinase 2)
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2205
    Sphingosine 1-phosphate phosphatase
    http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=778
        Enzymes
                SGPP1(sphingosine-1-phosphate phosphatase 1)
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2523
                SGPP2(sphingosine-1-phosphate phosphatase 2)
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2524
    Sphingosine 1-phosphate lyase
    http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=777
        Enzymes
                sphingosine-1-phosphate lyase 1
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2522
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